Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 3/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | HPGD | P15428 | 3/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.52 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.52 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.52 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6865195 | 1.00 | KCNH2 (0.56) | KCNH2CYP2D6KDM4EALDH1A1HPGD | |
| SCHEMBL6966143 | 1.00 | KCNH2 (0.56) | KCNH2CYP2D6KDM4EALDH1A1HPGD | |
| SCHEMBL6975286 | 1.00 | KCNH2 (0.56) | KCNH2CYP2D6KDM4EALDH1A1HPGD | |
| SCHEMBL6971989 | 1.00 | KCNH2 (0.56) | KCNH2CYP2D6KDM4EALDH1A1HPGD | |
| SCHEMBL6971995 | 1.00 | KCNH2 (0.56) | KCNH2CYP2D6KDM4EALDH1A1HPGD | |
| SCHEMBL6963635 | 1.00 | KCNH2 (0.56) | KCNH2CYP2D6KDM4EALDH1A1HPGD | |
| SCHEMBL6975290 | 1.00 | KCNH2 (0.56) | KCNH2CYP2D6KDM4EALDH1A1HPGD | |
| SCHEMBL6971999 | 1.00 | KCNH2 (0.56) | KCNH2CYP2D6KDM4EALDH1A1HPGD | |
| SCHEMBL6963638 | 1.00 | KCNH2 (0.56) | KCNH2CYP2D6KDM4EALDH1A1HPGD | |
| SCHEMBL6969140 | 0.94 | KCNH2 (0.55) | KCNH2SLC2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030203917-A1 | Compounds and methods for the treatment of neoplastic disease | SMITHKLINE BEECHAM CORPORATION AND SMITHKLINE BEECHAM P.L.C. | 2003-10-30 | — | — | US | claimed |
| EP-1051413-B1 | QUINOLINE DERIVATIVES AS ANTIBACTERIALS | SMITHKLINE BEECHAM PLC (GB) | 2003-06-04 | — | — | EP | claimed |
| US-20030203917-A1 | Compounds and methods for the treatment of neoplastic disease | SMITHKLINE BEECHAM CORPORATION AND SMITHKLINE BEECHAM P.L.C. | 2003-10-30 | — | — | US | disclosed |
| EP-1051413-B1 | QUINOLINE DERIVATIVES AS ANTIBACTERIALS | SMITHKLINE BEECHAM PLC (GB) | 2003-06-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030203917-A1 | Compounds and methods for the treatment of neoplastic disease | TOP1, TOP2A, TOP2B | KCNH2 4586/4885CYP2D6 2396/4885KDM4E 3544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.